The 4 linked references in paper O. Kirsanova V., V. Omelyanovsky V., О. Кирсанова В., В. Омельяновский В. (2018) “Анализ проблемы регулирования доступа к биосимилярам и пути решения // Options to optimize the access to biosimilars: analysis and solutions” / spz:neicon:pharmacoeconomics:y:2018:i:1:p:50-55

  1. 15. URL: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/ global-medicines-use-in-2020.pdf?la=uk-ua&hash=968B71C0B0769A17 9F3A56E331C62754EEF74752. Accessed: 05.01.2018. 2. Sura M. V., Maksimova L. V., Nazarov V. S. Medicinskie tekhnologii. Ocenka i vybor (in Russian). 2013; 2 (12): 73-83.
  2. Vorob’ev I. I., Semikhin A. S., Golovina E. O. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction (in Russian). 2017; 11 (3): 116-126. DOI:10.17749/23137347.2017.11.3.116-126.
  3. Podkorytov A. B., Zhilyaev O. V., Polzikov M. A. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. (in Russian). 2017; 11 (4): 35-42. DOI: 10.17749/2313-7347.2017.11.4.035-042.
  4. Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars». URL: http://sci-hub.tw/https://doi. org/10.1080/14712598.2017.1341486. Accessed: 08.01.2018. Сведения об авторах: